Clinuvel Pharmaceuticals (CUVL) Stock Overview
A biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CUVL from our risk checks.
CUVL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$5.95 |
| 52 Week High | AU$8.92 |
| 52 Week Low | AU$5.80 |
| Beta | 0.56 |
| 1 Month Change | -10.93% |
| 3 Month Change | -4.90% |
| 1 Year Change | -16.55% |
| 3 Year Change | -44.39% |
| 5 Year Change | -79.98% |
| Change since IPO | -9.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUVL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.7% | -5.9% | -2.2% |
| 1Y | -16.5% | 34.6% | 13.1% |
Return vs Industry: CUVL underperformed the US Biotechs industry which returned 34.6% over the past year.
Return vs Market: CUVL underperformed the US Market which returned 13.1% over the past year.
Price Volatility
| CUVL volatility | |
|---|---|
| CUVL Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CUVL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CUVL's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
| CUVL fundamental statistics | |
|---|---|
| Market cap | US$290.83m |
| Earnings (TTM) | US$24.33m |
| Revenue (TTM) | US$67.44m |
Is CUVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUVL income statement (TTM) | |
|---|---|
| Revenue | AU$94.02m |
| Cost of Revenue | AU$15.81m |
| Gross Profit | AU$78.21m |
| Other Expenses | AU$44.29m |
| Earnings | AU$33.92m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 83.18% |
| Net Profit Margin | 36.07% |
| Debt/Equity Ratio | 0% |
How did CUVL perform over the long term?
See historical performance and comparisonDividends
Does CUVL pay a reliable dividends?
See CUVL dividend history and benchmarks| Clinuvel Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Sep 08 2026 |
| Dividend Pay Date | Sep 28 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 16 days |
Does CUVL pay a reliable dividends?
See CUVL dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 00:07 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clinuvel Pharmaceuticals Limited is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Madeleine Williams | Canaccord Genuity |